Track the HLB생명과학 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, HLB생명과학 has logged 14 public disclosures. Market capitalisation: €477.9bn. The latest transaction was reported on 1 July 2026 (Other). Among the most active insiders: HLB. All data is free.
14
Insider Decl.
n/a
Thresholds
n/a
2 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HLB생명과학 Strong Buy (bullish), based on 1 analysts. Average price target: ₩24,300.
Fundamental score
Ranked 27,313 of 29,156 companies
17.5
score / 100
Value
19
Quality
16
FCF yld-6.5%
Earn yld-7.0%
EV/EBITDA·
ROE-14%
Gross mgn13%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HLB Life Science is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX exchange. It focuses on developing innovative solutions for disease treatment.